Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 USD | +4.97% | -11.05% | -9.14% |
04-22 | Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder | MT |
04-12 | Top Premarket Decliners | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 6.53M 8.92M |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.19M | Net income 2025 * | -9M -12.29M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.81
x | P/E ratio 2025 * |
-1.01
x | Employees | 6 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.96% |
1 day | +4.97% | ||
1 week | -11.05% | ||
Current month | +27.07% | ||
1 month | +37.40% | ||
3 months | +36.29% | ||
6 months | -13.33% | ||
Current year | -9.14% |
Managers | Title | Age | Since |
---|---|---|---|
Bankole Johnson
FOU | Founder | 64 | 10-10-31 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Joseph Truluck
DFI | Director of Finance/CFO | 46 | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jack W. Reich
LAW | General Counsel | - | 20-05-18 |
Cary Claiborne
CEO | Chief Executive Officer | 64 | 21-11-01 |
Tony Goodman
COO | Chief Operating Officer | 60 | 17-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.69 | +4.97% | 203 255 |
24-04-26 | 1.61 | -6.94% | 246,196 |
24-04-25 | 1.73 | +1.17% | 139,805 |
24-04-24 | 1.71 | +0.59% | 152,160 |
24-04-23 | 1.7 | -10.53% | 440,090 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.14% | 6.53M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ADIL Stock